AMPIVIEW® RNA probes
Enabling Your Projects 
GMP Services
Bulk Solutions
Research Travel Grant
Have You Published Using an Enzo Product?
Palbociclib, also known as PD0332991, is an orally available pyridopyrimidine-derived cyclin-dependent kinase (CDK) inhibitor with potential antineoplastic activity.
Shipping: Available products typically ship within 24/48h, via priority shipping.
Do you need support? Contact Customer Service or Technical Support.
Online Account
Access or Create Your Account
| Regulatory Status |
RUO – Research Use Only |
|---|
Resources
Metabolism
Download Resource
Cellular Therapy
Download Resource
Cardiovascular Research
Download Resource
Drug Discovery
Download Resource
AMPIVIEW® RNA Probes
Download Resource
Immuno-Oncology
Download Resource
AMPIGENE® PCR Solutions
Download Resource
Bioprocess
Download ResourceRelated Products
| CAS | 38966-21-1 |
|---|---|
| Couple Type | Inhibitor |
| Purity | ≥98% (TLC) |
| Alternative Name | (3R,4R)-4-[(3,4-Dimethoxyphenyl)methyl]dihydro-3-[(4-hydroxy-3-methoxyphenyl)methyl]-2-(3H)-furanone |
|---|---|
| CAS | 7770-78-7 |
| Couple Type | Inhibitor |
| Purity | ≥97% (HPLC) |
| Alternative Name | (3R,4R)-4-[(3,4-Dimethoxyphenyl)methyl]-3-[[4-(β-D-glucopyranosyloxy)-3-methoxyphenyl]methyl]dihydro-2(3H)-furanone |
|---|---|
| CAS | 20362-31-6 |
| Couple Type | Inhibitor |
| Purity | ≥95% (HPLC) |